Citation & Authors
Ann Am Thorac Soc. 2025;22(6):846-854.
ABSTRACT · RESEARCH SUMMARY
Research summary
Using Taiwanese National Health Insurance data, the study matched 1,288 pairs of patients with diabetes and COPD. SGLT2 inhibitors were associated with a lower risk of the composite of COPD hospitalization, ventilation, or death (aHR 0.79; 95% CI 0.67–0.93). Noninvasive ventilation, COPD hospitalization, and death were also less frequent. The findings support further evaluation of their role in this comorbid population.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
